FrancophonIA/ELRC3.0 huggingface dataset:
English: It must also not be used in patients who are suspected to have had in the past an allergic reaction called ‘allergic contact dermatitis' to Exelon patch.
Slovenian: Prav tako ga ne smejo ga uporabljati bolniki, pri katerih obstaja sum, da so v preteklosti doživeli alergijsko reakcijo, imenovano „alergijski kontaktni dermatitis“, na obliže zdravila Exelon.
English: Treatment should only be started if a caregiver is available who will regularly monitor the use of Rivastigmine Hexal by the patient.
Slovenian: Zdravljenje se lahko začne samo, če je na voljo negovalec, ki bo pri bolniku redno spremljal uporabo zdravila Rivastigmine Hexal.
English: The Committee initially concluded that for the treatment of dementia due to Parkinson's disease, Rivastigmine Hexal's benefits did not outweigh its risks.
Slovenian: Odbor je prvotno sklenil, da za zdravljenje demence, ki je posledica Parkinsonove bolezni, koristi zdravila Rivastigmine Hexala ne odtehtajo njegovih tveganj.
English: Rivastigmine Hexal was more effective than placebo at controlling symptoms.
Slovenian: Zdravilo Rivastigmine Hexal je bilo pri obvladovanju simptomov učinkovitejše od placeba.
English: Overall, the most common side effects include nausea (feeling sick, seen in 38 patients in 100) and vomiting (seen in 23 patients in 100), particularly during the phase when the dose of Rivastigmine Hexal is being increased.
Slovenian: Na splošno sta med najpogostejšimi neželenimi učinki navzeja (slabost, opažena pri 38 bolnikih od 100) in bruhanje (opaženo pri 23 bolnikih od 100), zlasti v obdobju povečevanja odmerka zdravila Rivastigmine Hexal.
English: For more information about treatment with Rivastigmine Hexal, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Rivastigmine Hexal preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: All of the studies lasted six months and compared the effects of Rivastigmine Hexal with those of placebo (a dummy treatment).
Slovenian: Vse študije so trajale šest mesecev, v njih pa so primerjali učinke zdravila Rivastigmine Hexal z učinki placeba (zdravila brez zdravilne učinkovine).
English: Therefore, the Committee decided that Rivastigmine Hexal's benefits are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: Odbor je zato sklenil, da so koristi zdravila Rivastigmine Hexal večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
English: In patients with Alzheimer's dementia or dementia due to Parkinson's disease, certain nerve cells die in the brain, resulting in low levels of the neurotransmitter acetylcholine (a chemical that allows nerve cells to communicate with each other).
Slovenian: Pri bolnikih z Alzheimerjevo demenco ali demenco zaradi Parkinsonove bolezni v možganih odmirajo določene živčne celice, zaradi česar se znižajo ravni živčnega prenašalca acetilholina (kemične snovi, ki omogoča medsebojno komunikacijo med živčnimi celicami).
English: Other information about Rivastigmine Hexal
Slovenian: Druge informacije o zdravilu Rivastigmine Hexal
English: The CHMP concluded that Rivastigmine Hexal has a modest effectiveness in treating the symptoms of Alzheimer's dementia, although this does reflect an important benefit in some patients.
Slovenian: CHMP je zaključil, da ima zdravilo Rivastigmine Hexal pri zdravljenju simptomov Alzheimerjeve demence skromen učinek, čeprav ta pomeni pomembno korist za nekatere bolnike.
English: Rivastigmine Hexal must not be used in people who are hypersensitive (allergic) to rivastigmine, other carbamate derivatives or any of the other ingredients.
Slovenian: Zdravila Rivastigmine Hexal ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) rivastigmin, druge derivate karbamata ali katero koli drugo sestavino zdravila.
English: Treatment with Rivastigmine Hexal should be initiated and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer's disease or dementia in patients with Parkinson's disease.
Slovenian: Zdravljenje z zdravilom Rivastigmine Hexal mora uvesti in nadzorovati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem Alzheimerjeve bolezni ali demence pri bolnikih s Parkinsonovo boleznijo.
English: Rivastigmine Hexal is used for the treatment of patients with mild to moderately severe Alzheimer's dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.
Slovenian: Zdravilo Rivastigmine Hexal se uporablja za zdravljenje bolnikov z blago do zmerno hudo Alzheimerjevo demenco, tj. napredujočo okvaro možganov, ki postopoma prizadene spomin, intelektualne zmožnosti in vedenje.
English: An additional study in 27 patients was used to show that Rivastigmine Hexal capsules and oral solution produced similar levels of the active substance in the blood.
Slovenian: Z dodatno študijo s 27 bolniki so dokazali, da kapsule in peroralna raztopina zdravila Rivastigmine Hexal dosegajo podobne ravni zdravilne učinkovine v krvi.
English: Rivastigmine Hexal has been studied in three main studies involving 2,126 patients with mild to moderately severe Alzheimer's disease.
Slovenian: Zdravilo Rivastigmine Hexal so proučevali v treh glavnih študijah, v katerih je sodelovalo 2 126 bolnikov z blago do zmerno hudo obliko Alzheimerjeve bolezni.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Rivastigmine Hexal.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Rivastigmine Hexal, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: Rivastigmine Hexal was also studied in 541 patients with dementia due to Parkinson's disease.
Slovenian: Zdravilo Rivastigmine Hexal so proučevali tudi pri 541 bolnikih z demenco kot posledico Parkinsonove bolezni.
English: Rivastigmine Hexal is a medicine containing the active substance rivastigmine.
Slovenian: Rivastigmine Hexal je zdravilo, ki vsebuje zdravilno učinkovino rivastigmin.
English: What benefit has Rivastigmine Hexal shown during the studies?
Slovenian: Kakšne koristi je zdravilo Rivastigmine Hexal izkazalo med študijami?
English: The global symptom score also improved more in the patients taking Rivastigmine Hexal.
Slovenian: Tudi rezultat celostne ocene simptomov je bil boljši pri bolnikih, ki so jemali zdravilo Rivastigmine Hexal.
English: In the three studies of Rivastigmine Hexal in patients with Alzheimer's dementia, patients taking doses of Rivastigmine Hexal between 6 and 9 mg per day had an average increase in cognitive symptoms of 0.2 points from a baseline of 22.9 points at the start of the study, where a lower score indicates better performance.
Slovenian: V treh študijah zdravila Rivastigmine Hexal pri bolnikih z Alzheimerjevo demenco je bilo pri tistih, ki so jemali od 6- do 9-miligramske odmerke zdravila Rivastigmine Hexal, opaziti povprečno povečanje kognitivnih simptomov za 0,2 točke od izhodiščne vrednosti 22,9 točk na začetku študije, pri čemer nižji rezultat pomeni boljšo učinkovitost.
English: By blocking these enzymes, Rivastigmine Hexal allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer's dementia and dementia due to Parkinson's disease.
Slovenian: Zdravilo Rivastigmine Hexal z blokiranjem teh encimov omogoča, da se ravni acetilholina v možganih povečajo, zaradi česar se simptomi Alzheimerjeve demence in demence zaradi Parkinsonove bolezni ublažijo.
English: The patients with dementia due to Parkinson's disease taking Rivastigmine Hexal capsules showed an improvement in cognitive symptoms of 2.1 points, compared with a worsening of 0.7 points in those taking placebo, from a baseline of around 24 points.
Slovenian: Pri bolnikih z demenco zaradi Parkinsonove bolezni, ki so jemali kapsule zdravila Rivastigmine Hexal, je bilo opaziti izboljšanje kognitivnih simptomov za 2,1 točke, v primerjavi s poslabšanjem za 0,7 točke pri tistih, ki so jemali placebo, od izhodiščne vrednosti približno 24 točk.
English: Rivastigmine Hexal is also used to treat mild to moderately severe dementia in patients with Parkinson's disease.
Slovenian: Zdravilo se lahko uporablja tudi za zdravljenje blage do zmerno hude demence pri bolnikih s Parkinsonovo boleznijo.
English: The active substance in Rivastigmine Hexal, rivastigmine, is an antidementia medicine.
Slovenian: Zdravilna učinkovina zdravila Rivastigmine Hexal, rivastigmin, je zdravilo proti demenci.
English: For the global score, patients taking Rivastigmine Hexal had an increase in symptoms of 4.1 points, compared with 4.4 in those taking placebo.
Slovenian: Kar zadeva rezultat celostne ocene simptomov, je pri bolnikih, ki so jemali zdravilo Rivastigmine Hexal, prišlo do povečanja simptomov za 4,1 točke v primerjavi s 4,4 točke pri tistih, ki so jemali placebo.
English: For the full list of all side effects reported with Rivastigmine Hexal, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Rivastigmine Hexal, glejte navodilo za uporabo.
English: In patients who tolerate this dose, it can be increased in 1.5-mg steps no more frequently than every two weeks, to a regular dose of 3 to 6 mg twice a day.
Slovenian: Pri bolnikih, ki prenašajo navedeni odmerek, se lahko ta postopoma povečuje za 1,5 mg, vendar ne pogosteje kot vsaka dva tedna, dokler ni dosežen stalni odmerek 3 do 6 mg dvakrat na dan. Za dosego največje učinkovitosti se uporabi največji odmerek, ki ga bolnik še prenaša, vendar ta ne sme preseči 6 mg dvakrat na dan.
English: The types of side effects seen with Rivastigmine Hexal depend on the type of dementia it is being used to treat.
Slovenian: Vrste neželenih učinkov, opaženih pri zdravilu Rivastigmine Hexal, so odvisne od vrste demence, ki se zdravi.
English: What is the risk associated with Rivastigmine Hexal?
Slovenian: Kakšna tveganja so povezana z zdravilom Rivastigmine Hexal?
English: Why has Rivastigmine Hexal been approved?
Slovenian: Zakaj je bilo zdravilo Rivastigmine Hexal odobreno?
English: What is Rivastigmine Hexal used for?
Slovenian: Za kaj se zdravilo Rivastigmine Hexal uporablja?
English: How has Rivastigmine Hexal been studied?
Slovenian: Kako je bilo zdravilo Rivastigmine Hexal raziskano?
English: What is Rivastigmine Hexal?
Slovenian: Kaj je zdravilo Rivastigmine Hexal?
English: How is Rivastigmine Hexal used?
Slovenian: Kako se zdravilo Rivastigmine Hexal uporablja?
English: How does Rivastigmine Hexal work?
Slovenian: Kako zdravilo Rivastigmine Hexal deluje?
English: What measures are being taken to ensure the safe and effective use of Ciambra?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Ciambra?
English: Ciambra is a cancer medicine used to treat two types of lung cancer:
Slovenian: Ciambra je zdravilo proti raku, ki se uporablja za zdravljenje dveh vrst pljučnega raka:
English: Other information about Ciambra
Slovenian: Druge informacije o zdravilu Ciambra
English: The full EPAR and risk management plan summary for Ciambra can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Ciambra sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The Committee recommended that Ciambra be approved for use in the EU.
Slovenian: Priporočil je, da se zdravilo Ciambra odobri za uporabo v EU.
English: For more information on generic medicines, see the question-and-answer document here.
Slovenian: Za več informacij o generičnih zdravilih si oglejte dokument z vprašanji in odgovori, ki je na voljo tukaj
English: This means that Ciambra is similar to a ‘reference medicine' already authorised in the European Union (EU) called Alimta.
Slovenian: To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Alimta.
English: Because Ciambra is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Slovenian: Ker je zdravilo Ciambra generično zdravilo, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Ciambra has been shown to be comparable to Alimta.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da je zdravilo Ciambra primerljivo z zdravilom Alimta.
English: What are the benefits and risks of Ciambra?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom Ciambra?
English: Ciambra is a ‘generic medicine'.
Slovenian: Zdravilo Ciambra je „generično zdravilo“.
English: A risk management plan has been developed to ensure that Ciambra is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Ciambra je bil pripravljen načrt obvladovanja tveganj.
English: This is a summary of the European public assessment report (EPAR) for Ciambra.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Ciambra.
English: It is not intended to provide practical advice on how to use Ciambra.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: What is Ciambra and what is it used for?
Slovenian: Kaj je zdravilo Ciambra in za kaj se uporablja?
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Ciambra, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Ciambra in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: Why is Ciambra approved?
Slovenian: Zakaj je bilo zdravilo Ciambra odobreno?
English: For practical information about using Ciambra, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Ciambra naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: To reduce side effects, patients should take a corticosteroid (a type of medicine that reduces inflammation) and folic acid (a type of vitamin), and receive injections of vitamin B12 during treatment with Ciambra.
Slovenian: Da bi zmanjšali neželene učinke, morajo bolniki med zdravljenjem z zdravilom Ciambra jemati kortikosteroid (vrsto zdravila, ki ublaži vnetje) in folno kislino (vrsto vitamina) ter prejemati injekcije vitamina B12.
English: For more information about treatment with Ciambra, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Ciambra preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: When Ciambra is given with cisplatin, an ‘anti-emetic' medicine (to prevent vomiting) and fluids (to prevent dehydration) should also be given before or after the cisplatin dose.
Slovenian: Kadar se zdravilo Ciambra daje v kombinaciji s cisplatinom, je treba pred odmerkom cisplatina ali po njem vzeti tudi antiemetično zdravilo (za preprečevanje bruhanja) in zaužiti tekočino (za preprečevanje dehidracije).
English: The active substance in Ciambra, pemetrexed, is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells), which belongs to the group ‘antimetabolites'.
Slovenian: Zdravilna učinkovina zdravila Ciambra, pemetreksed, je citotoksik (zdravilo, ki uničuje celice, ki se delijo, kot na primer rakave celice) iz skupine „antimetabolitov“.
English: Ciambra is available as a powder that is made up into a solution for infusion (drip) into a vein.
Slovenian: Zdravilo Ciambra je na voljo v obliki praška za pripravo raztopine za infundiranje (kapalne infuzije) v veno.
English: How does Ciambra work?
Slovenian: Kako zdravilo Ciambra deluje?
English: Ciambra pemetrexed
Slovenian: Ciambra pemetreksed
English: Ciambra contains the active substance pemetrexed.
Slovenian: Zdravilo Ciambra vsebuje zdravilno učinkovino pemetreksed.
English: How has Ciambra been studied?
Slovenian: Kako je bilo zdravilo Ciambra raziskano?
English: How is Ciambra used?
Slovenian: Kako se zdravilo Ciambra uporablja?
English: No additional studies were needed as Ciambra is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Alimta.
Slovenian: Ker je zdravilo Ciambra generično zdravilo, ki se daje z infundiranjem in vsebuje isto zdravilno učinkovino kot referenčno zdravilo Alimta, niso bile potrebne nobene dodatne študije.
English: 400 mg Powder for concentrate for solution for infusion
Slovenian: 400 mg prašek za koncentrat za raztopino za infundiranje intravenska uporaba stekleni viali
English: Movymia teriparatide
Slovenian: Movymia teriparatid
English: • men who are at an increased risk of fractures;
Slovenian: • moških s povečanim tveganjem za zlom;
English: Movymia must not be used during pregnancy or breastfeeding.
Slovenian: Ne sme se uporabljati med nosečnostjo in dojenjem.
English: This means that Movymia is highly similar to a biological medicine (also known as the ‘reference medicine') that is already authorised in the European Union (EU).
Slovenian: To pomeni, da je zelo podobno biološkemu zdravilu (t.i. „referenčnemu zdravilu“), ki je že odobreno v Evropski uniji (EU).
English: What measures are being taken to ensure the safe and effective use of Movymia?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Movymia?
English: The full EPAR for Movymia can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Movymia je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This was considered sufficient to conclude that Movymia will behave in the same way in terms of effectiveness and safety.
Slovenian: To je zadostovalo za zaključek, da se bo zdravilo Movymia z vidika učinkovitosti in varnosti vedlo na enak način.
English: It also increases the absorption of calcium from food and prevents too much calcium being lost in the urine.
Slovenian: Poleg tega poveča absorpcijo kalcija iz hrane in preprečuje izgubo velike količine kalcija z urinom.
English: Patients may inject themselves once they have been trained.
Slovenian: Bolniki si lahko zdravilo injicirajo sami, potem ko so bili za to ustrezno usposobljeni.
English: This is a summary of the European public assessment report (EPAR) for Movymia.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Movymia.
English: • men and women who are at an increased risk of fractures due to long-term treatment with glucocorticoids (a type of steroid).
Slovenian: • moških in ženskah, ki imajo povečano tveganje za zlome zaradi dolgotrajnega zdravljenja z glukokortikoidi (vrsto steroida).
English: The most common side effect with Movymia (seen in more than 1 patient in 10) is pain in the arms or legs.
Slovenian: Najpogostejši neželeni učinek zdravila Movymia (opažen pri več kot 1 bolniku od 10) so bolečine v rokah ali nogah.
English: A study in 54 healthy women has shown that the same doses of the two medicines given by injection under the skin produced similar levels of the active substance teriparatide in the body.
Slovenian: Študija na 54 zdravih ženskah je pokazala, da so enaki odmerki obeh zdravil, dani z injiciranjem pod kožo, povzročili podobno raven učinkovine teriparatid v telesu.
English: What benefits of Movymia have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Movymia izkazalo v študijah?
English: It is not intended to provide practical advice on how to use Movymia.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: What are the risks associated with Movymia?
Slovenian: Kakšna tveganja so povezana z zdravilom Movymia?
English: Movymia must not be used in patients who have other bone diseases such as Paget's disease, bone cancer or bone metastases (cancer that has spread to the bone), patients who have had radiation therapy of the skeleton, or patients who have hypercalcaemia (high blood calcium levels), unexplained high levels of alkaline phosphatase (an enzyme) or severe kidney disease.
Slovenian: Zdravilo Movymia se ne sme uporabljati pri bolnikih, ki imajo druga obolenja kosti, kot so Pagetova bolezen, kostni rak ali metastaze v kosteh (rak, ki se je razširil na kosti), bolnikih, ki so bili na obsevanju okostja, ali bolnikih, ki imajo hiperkalciemijo (visoke ravni kalcija v krvi), tistih z nepojasnjeno visokimi ravnmi alkalne fosfataze (vrste encima) ali hudim obolenjem ledvic.
English: Thus, as for Forsteo, the benefit outweighs the identified risks and the Committee recommended that Movymia be given marketing authorisation.
Slovenian: Tako njegove koristi enako kot pri zdravilu Forsteo odtehtajo znana tveganja, zato je Odbor priporočil, da se za zdravilo Movymia izda dovoljenje za promet.
English: The two-year course of Movymia should be given only once during a patient's lifetime.
Slovenian: Dveletno zdravljenje z zdravilom Movymia se sme pri bolniku uporabiti le enkrat v življenju.
English: What is Movymia and what is it used for?
Slovenian: Kaj je zdravilo Movymia in za kaj se uporablja?
English: Other information about Movymia
Slovenian: Druge informacije o zdravilu Movymia
English: • women who have been through the menopause.
Slovenian: • ženskah po menopavzi.
English: For more information about treatment with Movymia, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Movymia preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: Why is Movymia approved?
Slovenian: Zakaj je bilo zdravilo Movymia odobreno?
English: Movymia is a medicine used for the treatment of osteoporosis (a disease that makes bones fragile) in:
Slovenian: Zdravilo Movymia se uporablja za zdravljenje osteoporoze (bolezni, ki povzroča krhkost kosti) pri:
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Movymia have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Movymia upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: In these patients, Movymia has been shown to significantly reduce vertebral (spine) and non-vertebral fractures (broken bones), but not those of the hip;
Slovenian: Pri teh bolnicah je bilo dokazano, da zdravilo Movymia znatno zmanjšuje pojavnost zlomov vretenc (hrbtenice) in nevretenčnih zlomov (zlomov kosti), ne pa tudi zlomov kolka;
English: Because Movymia is a biosimilar medicine, the studies on effectiveness and safety of teriparatide carried out with Forsteo do not need to be repeated for Movymia.
Slovenian: Zdravilo Movymia je „podobno biološko zdravilo“, zato študij o učinkovitosti in varnosti teriparatida, izvedenih z zdravilom Forsteo, z zdravilom Movymia ni treba ponavljati.
English: Gradually, the bones become less dense and more likely to break.
Slovenian: Kosti se tako postopoma redčijo in postajajo krhkejše ter posledično bolj lomljive.